A New Lyme Disease Vaccine Is on the Horizon

The First Lyme Vaccine: A Brief History

To understand why this moment matters, it helps to look back. In 1998, the FDA approved LYMErix, the first and only Lyme disease vaccine ever licensed in the United States. The vaccine used an outer surface protein from the Borrelia burgdorferi bacterium (called OspA) to prime the immune system to neutralize the bacteria before it could leave a tick and enter the human body. 

In clinical trials, LYMErix was roughly 78% effective at preventing Lyme disease after a full three-dose series.

Despite these results, LYMErix was voluntarily withdrawn from the market by GlaxoSmithKline in 2002, just four years after approval. Sales had collapsed, driven largely by media coverage of concerns that the vaccine might trigger an autoimmune form of arthritis. 

The theory centered on the idea that OspA might cross-react with proteins in human joints, producing joint inflammation that looked a lot like chronic Lyme disease itself. Though the FDA found no conclusive evidence of a causative link, public confidence eroded and lawsuits followed. But the concerns, whether or not they were ever fully proven, left a lasting mark on how patients and clinicians think about Lyme vaccination.

The withdrawal of LYMErix left millions of Americans without a preventive option against one of the most common vector-borne diseases in the Northern Hemisphere.

Introducing VLA15 / LB6V: The New Candidate

The most advanced Lyme vaccine in development today is known as VLA15 (recently renamed LB6V), co-developed by Pfizer and Valneva. Like LYMErix, it uses OspA as its primary antigen,  the same protein that raised concerns the first time around. However, it has been engineered specifically to reduce the risk of cross-reactivity with human joint proteins, with the goal of avoiding the autoimmune arthritis concerns that plagued its predecessor.

VLA15 is also a 6-valent vaccine, meaning it targets six OspA serotypes found in Borrelia species across North America and Europe, providing broader coverage than the original single-serotype LYMErix. 

The vaccine works by stimulating antibodies that neutralize Lyme bacteria while they are still inside the tick, before the bacteria have a chance to enter the human bloodstream.

Phase 3 Trial Results: Promising, But Questions Remain

In early 2026, Pfizer and Valneva announced topline Phase 3 results from the VALOR trial (Vaccine Against Lyme for Outdoor Recreationists), which enrolled 9,437 participants aged five and older across the United States, Canada, and Europe. 

The trial reported efficacy of over 73% in reducing confirmed Lyme disease cases, and no major safety signals were identified at the time of analysis. Pfizer is now planning regulatory submissions to the FDA and European Medicines Agency in 2026.

While these numbers are encouraging on the surface, it is important to view them with the caution they deserve. The studies have only just completed Phase 3, and the trial population and follow-up period may not have been large enough or long enough to determine whether the autoimmune and joint-related problems seen with the original vaccine will re-emerge over time. 

The redesign of VLA15 looks promising, but promising is not the same as proven, particularly when the concern involves delayed immune phenomena that can take years to manifest. There are remaining concerns that the Osp-A though it may not react with joints may still activate Toll like receptor 4 and cause persistent immune activation.

“The current studies are just finished phase three and there weren’t enough people and not long enough to know for sure if these things are going to pop up.” — Dr. Eric Gordon

What the Dosing Schedule Looks Like

Another practical consideration is the required dosing schedule. The VALOR trial used a four-dose series: three doses during the first year (at months 0, 2, and 5–9), followed by a booster dose approximately one year later, timed just before peak Lyme season. That amounts to roughly two injections per year, and it is not yet clear whether annual boosting will be required indefinitely to maintain protection.

This pattern is consistent with how many protein subunit vaccines behave: strong immune response immediately after vaccination, followed by waning antibody levels over time. Similar, in that respect, to what we observed with COVID vaccines. The need for repeated annual dosing is a real consideration, particularly for patients whose immune systems are already under strain.

A Clinical Perspective: Considerations for Patients with Chronic Lyme or Immune Dysfunction

Here at Gordon Medical, we care for many patients living with persistent symptoms following Lyme disease infection, which is often referred to as Post-Treatment Lyme Disease Syndrome (PTLDS) or chronic Lyme disease. For this population, any new vaccine warrants thoughtful consideration rather than reflexive enthusiasm or reflexive rejection.

An important and often-overlooked clinical point to highlight is that the very patients who most want protection from Lyme disease may also be the ones whose immune systems are least well-positioned to respond straightforwardly to a new vaccine. Here is why:

• People who experience persistent symptoms after Lyme infection tend to have immune systems that struggle to turn off the innate immune response, the first-line, inflammatory arm of immunity. This chronic low-grade activation is central to many of the symptoms these patients experience.
• When the innate immune system remains persistently activated, the acquired (adaptive) immune system is often downregulated as a compensatory mechanism to prevent the body from further damaging its own tissues. This adaptive downregulation is precisely the mechanism required to tolerate vaccines well over time.
• For robust, healthy individuals, VLA15 may well represent a safe and meaningful advance, particularly if the redesign has genuinely resolved the autoimmune arthritis concern from the original vaccine.
• For those with dysregulated immune function, the longer-term effects of repeated annual vaccination on immune balance are not yet known. The Phase 3 trial was not designed to answer this question for this specific population.

None of this means the vaccine should be categorically avoided; it means the decision deserves to be made individually, with a clinician who knows your immune history and can weigh your specific risks and needs.

The Bottom Line: Watch and Wait

Our overall recommendation is straightforward: keep your eyes open and wait to see how things develop over time. This is not a dismissal of the vaccine; it is a recognition that for a community of patients who have already experienced the consequences of immune dysfunction, caution is not the same as inaction. It is prudent medicine.

Lyme disease affects an estimated 476,000 Americans annually, and the absence of a preventive vaccine for over two decades has been a genuine gap in public health. A new option, if it proves safe across diverse populations and over longer time horizons, would be a meaningful development. But we are not there yet, and the history of LYMErix is a reminder that early enthusiasm does not always hold up under the weight of real-world experience.

We will continue tracking the regulatory process and emerging post-approval data closely. 

More Lyme Resources

• Gordon Medical Lyme Hub
• Gordon Medical Forum Ask Me Anything: Lyme Disease Therapeutic Strategies with Dr. Steven Harris
• Gordon Medical Forum Podcast Addressing Lyme Testing Challenges with Dr. Nafysa Parpia and Dr. Joseph Burrascano
• Plasmapheresis Advanced Therapy for Lyme & Tick-Borne Diseases